FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $40.93, for a total transaction of $1,227,900.00. Following the sale, the chief executive officer now owns 2,646,320 shares of the company’s stock, valued at $108,313,877.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
FibroGen stock traded down $1.21 during midday trading on Friday, reaching $39.72. The stock had a trading volume of 14,197 shares, compared to its average volume of 448,505. FibroGen Inc has a twelve month low of $37.85 and a twelve month high of $68.55. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.76 and a current ratio of 6.76. The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of -22.87 and a beta of 2.13.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.15). FibroGen had a negative return on equity of 24.59% and a negative net margin of 87.84%. The firm had revenue of $29.00 million during the quarter, compared to analyst estimates of $36.48 million. The firm’s revenue for the quarter was down 28.6% on a year-over-year basis. Equities analysts forecast that FibroGen Inc will post -1.55 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. Trexquant Investment LP acquired a new position in FibroGen in the 3rd quarter worth approximately $201,000. Oppenheimer Asset Management Inc. acquired a new position in FibroGen in the 2nd quarter worth approximately $236,000. Pacer Advisors Inc. acquired a new position in FibroGen in the 3rd quarter worth approximately $246,000. Nisa Investment Advisors LLC boosted its stake in FibroGen by 1,829.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 6,174 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 5,854 shares during the period. Finally, Aperio Group LLC boosted its stake in FibroGen by 56.3% in the 2nd quarter. Aperio Group LLC now owns 7,004 shares of the biopharmaceutical company’s stock worth $438,000 after purchasing an additional 2,523 shares during the period. 64.86% of the stock is owned by hedge funds and other institutional investors.
A number of analysts recently weighed in on FGEN shares. ValuEngine cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, September 17th. Leerink Swann set a $82.00 target price on shares of FibroGen and gave the stock a “buy” rating in a report on Tuesday, September 11th. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 9th. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a report on Wednesday, October 17th. Finally, TheStreet cut shares of FibroGen from a “c-” rating to a “d+” rating in a report on Wednesday, November 21st. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. FibroGen presently has an average rating of “Buy” and an average target price of $72.25.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: FibroGen Inc (FGEN) CEO Sells 30,000 Shares of Stock” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/07/insider-selling-fibrogen-inc-fgen-ceo-sells-30000-shares-of-stock.html.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
See Also: What are the benefits of a balanced fund?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.